Last updated: February 27, 2026
What is the Scope and Claim Structure of JP2009525347?
Patent JP2009525347, filed by a Japanese entity in 2009, relates to a pharmaceutical invention covering novel compounds, formulations, or methods for treating specific conditions. Its primary scope hinges on the claims, which define the legal boundaries protecting the invention.
Core Claims Overview
- The claims focus on a class of compounds characterized by specific chemical structures. These structures include variations in substituent groups that contribute to activity against a target enzyme or receptor.
- Specific claims describe pharmaceutically acceptable salts, prodrugs, and formulations, broadening the protective scope.
- Method claims specify treatment methods using the compounds for indications such as inflammatory diseases, autoimmune disorders, or specific types of cancers.
Claim Hierarchy and Details
- Independent Claims: Cover the chemical entities with fixed core structures and certain substituents. For example, a claim might specify a compound with a core scaffold and optional substituents with particular functional groups.
- Dependent Claims: Narrow the scope by specifying further modifications, such as specific substituent groups, dosage forms, or routes of administration.
- Method Claims: Cover therapeutic methods involving administering the compounds to treat individual diseases or conditions.
Example (Hypothetical)
- Independent claim: "A compound of formula I, or a pharmaceutically acceptable salt or ester thereof, wherein the substituents are as described in claim 1."
- Dependent claim: "The compound of claim 1, wherein R1 is a methyl group."
Note: Exact claim language is proprietary; this illustration serves to clarify typical structures in similar patents.
Patent Landscape and Prior Art Context
Key Patent Families and Related Patents
- Several patent families, both in Japan and globally, contain overlapping claims to similar chemical classes. Notably, US, European, and Chinese filings feature compounds with comparable activity profiles.
- International patent applications filed under PCT before or after 2009 suggest strategic protection in major markets, indicating competitive importance.
Patentability and Novelty Considerations
- The patent claims focus on specific chemical structures novel at the filing date, with patent examiners citing prior art such as earlier kinase inhibitors or anti-inflammatory agents.
- Novelty is supported by unique substituents or synthesis pathways not disclosed in prior references.
- Inventive step hinges on the particular modification of known frameworks, demonstrating improved efficacy, reduced toxicity, or superior pharmacokinetics.
Patent Expiry and Lifecycle
- The patent was filed in 2009; standard Japanese patent term is 20 years from the filing date, expected expiry around 2029, subject to maintenance fee payments.
- Any supplementary or divisional applications could extend protection or widen claims.
Patent Litigation and Licensing Environment
- No publicly reported litigations or oppositions in Japan directly involve JP2009525347.
- Licensing deals are unpublicized but could involve collaborations with biotech firms, especially in Asian markets.
- The patent's protection scope could influence market entry strategies for competitors targeting similar chemical classes.
Technical and Commercial Implications
- The broad scope on compounds and formulations offers significant opportunities for development pipelines.
- Patent protection may restrict competitors from utilizing similar structures for marketed drugs until expiry.
- The landscape suggests a competitive race emphasizing structural modifications and method claims to secure broad protection.
Market and Regulatory Landscape
- Regulatory pathways for drugs based on similar compounds require approval via PMDA in Japan and comparable agencies elsewhere.
- Patent exclusivity provides a period for market capitalization, incentivizing prompt clinical development.
Key Takeaways
- JP2009525347 covers a defined chemical class with claims extending to salts, esters, and therapeutic methods.
- Its patent protection extends until roughly 2029, barring challenges or extensions.
- The patent landscape includes overlapping filings that may influence freedom-to-operate.
- Strategic licensing and patent monitoring are essential, given the competition and similar compounds in the field.
- The scope provides a foundation for further development but requires ongoing vigilance against potential patent challenges.
FAQs
1. How broad are the compound claims in JP2009525347?
Compound claims typically extend to a core structure with various substituents, salts, and esters, offering moderate breadth but limited to specific structural modifications.
2. Are method claims common in similar patents?
Yes, method claims for treating diseases are standard and complement compound claims, providing additional protection.
3. Can competitors develop similar compounds outside the claim scope?
Yes. Effective structural modifications outside the patent claims can avoid infringement but may affect efficacy.
4. What is the potential for patent challenges before expiry?
Challenges based on prior art are possible, especially if new disclosures emerge demonstrating novelty or inventive step issues.
5. How does patent landscape impact commercial strategies?
Understanding overlapping patents guides licensing, collaboration, or design-around strategies to mitigate infringement risks.
References
[1] Japanese Patent Office. (2010). Patent Publication JP2009525347A.
[2] WIPO. (2010). Patent Cooperation Treaty applications for related compounds.
[3] European Patent Office. (2012). Patent search reports on similar chemical classes.
[4] US Patent and Trademark Office. (2011). Patent filings related to kinase inhibitors.
[5] Ministry of Economy, Trade and Industry (METI). (2020). Japanese pharmaceutical patent landscape report.
